Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 544067 | NSE: INNOVACAP | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Innova Captab Ltd is a average quality company.
The key valuation ratios of Innova Captab Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Innova Captab Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 15% | 19.2% | 20.8% | 23.8% | 15.3% | - |
| Value Creation Index ⓘ | 0.1 | 0.4 | 0.5 | 0.7 | 0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||||
| Sales ⓘ | 357 | 373 | 411 | 785 | 859 | 859 |
| Sales YoY Gr. | - | 4.6% | 10% | 91.3% | 9.3% | - |
| Adj EPS ⓘ | 4 | 5.7 | 7.1 | 13.5 | 11.5 | 10.1 |
| YoY Gr. | - | 41.5% | 25.4% | 90.7% | -15.3% | - |
| BVPS (₹) ⓘ | 17.1 | 23 | 30.2 | 43.9 | 55.9 | 159.5 |
| Adj Net Profit ⓘ | 19.2 | 27.2 | 34.1 | 65 | 55.1 | 58 |
| Cash Flow from Ops. ⓘ | 18.9 | 30.8 | 41.6 | 58.3 | 39.3 | - |
| Debt/CF from Ops. ⓘ | 3.8 | 1.7 | 1.1 | 3 | 6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 32% | 9.3% | ||||
| Adj EPS ⓘ | NA | NA | 26.6% | -15.3% | ||||
| BVPSⓘ | NA | NA | 34.5% | 27.3% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 23.4 | 28.2 | 26.7 | 36.6 | 23 | 9.3 |
| Op. Profit Mgn % ⓘ | 11.2 | 13.6 | 13.3 | 12.5 | 11.5 | 12.7 |
| Net Profit Mgn % ⓘ | 5.4 | 7.3 | 8.3 | 8.3 | 6.4 | 6.7 |
| Debt to Equity ⓘ | 0.9 | 0.5 | 0.3 | 0.8 | 0.9 | - |
| Working Cap Days ⓘ | 0 | 158 | 198 | 140 | 169 | 44 |
| Cash Conv. Cycle ⓘ | 0 | 64 | 73 | 50 | 58 | 9 |
Sales growth is growing at healthy rate in last 3 years 32.00%
Net Profit is growing at healthy rate in last 3 years 26.55%
Debt to equity has declined versus last 3 years average to 0.88
Return on Equity has declined versus last 3 years average to 9.30%
Sales growth is not so good in last 4 quarters at -0.60%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 10.1 | 11.9 |
| TTM Sales (₹ Cr.) | 859 | 926 |
| BVPS (₹.) ⓘ | 159.5 | 176.4 |
| Reserves (₹ Cr.) ⓘ | 856 | 952 |
| P/BV ⓘ | 2.93 | 2.65 |
| PE ⓘ | 46.49 | 39.40 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 444.00 / 590.00 |
| All Time Low / High (₹) | 444.00 / 590.00 |
| Market Cap (₹ Cr.) | 2,676 |
| Equity (₹ Cr.) | 57.2 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 48.8 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|
| Sales | 357 | 373 | 411 | 785 | 859 |
| Operating Expenses ⓘ | 317 | 322 | 356 | 687 | 760 |
| Manufacturing Costs | 7 | 69 | 49 | 109 | 162 |
| Material Costs | 286 | 224 | 273 | 520 | 528 |
| Employee Cost | 17 | 20 | 22 | 37 | 44 |
| Other Costs ⓘ | 7 | 9 | 12 | 21 | 27 |
| Operating Profit ⓘ | 40 | 51 | 54 | 99 | 99 |
| Operating Profit Margin (%) | 11.1% | 13.6% | 13.3% | 12.5% | 11.5% |
| Other Income ⓘ | 0 | 1 | 1 | 3 | 9 |
| Interest ⓘ | 5 | 5 | 4 | 5 | 18 |
| Depreciation ⓘ | 11 | 10 | 6 | 7 | 11 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 24 | 38 | 46 | 89 | 78 |
| Tax ⓘ | 5 | 10 | 12 | 22 | 21 |
| Profit After Tax | 19 | 28 | 35 | 66 | 58 |
| PAT Margin (%) | 5.4% | 7.5% | 8.4% | 8.4% | 6.7% |
| Adjusted EPS (₹) | 4.0 | 5.8 | 7.2 | 13.8 | 12.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 82 | 110 | 145 | 211 | 268 | |||||
| Share Capital ⓘ | 12 | 12 | 12 | 12 | 48 | |||||
| Reserves ⓘ | 70 | 98 | 133 | 199 | 220 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |||||
| Debt | 66 | 48 | 39 | 165 | 232 | |||||
| Long Term Debt | 39 | 12 | 6 | 67 | 134 | |||||
| Short Term Debt | 26 | 36 | 33 | 98 | 98 | |||||
| Trade Payables | 60 | 72 | 112 | 140 | 148 | |||||
| Others Liabilities ⓘ | 20 | 24 | 73 | 40 | 71 | |||||
| Total Liabilities ⓘ | 228 | 254 | 370 | 556 | 719 | |||||
Fixed Assets | ||||||||||
| Gross Block | 119 | 83 | 96 | 185 | 196 | |||||
| Accumulated Depreciation | 40 | 10 | 16 | 24 | 34 | |||||
| Net Fixed Assetsⓘ | 78 | 73 | 79 | 161 | 161 | |||||
| CWIP ⓘ | 0 | 0 | 7 | 0 | 22 | |||||
| Investmentsⓘ | 0 | 0 | 0 | 60 | 60 | |||||
| Inventories | 33 | 65 | 91 | 105 | 97 | |||||
| Trade Receivables | 95 | 87 | 139 | 174 | 230 | |||||
| Cash Equivalents | 1 | 5 | 12 | 2 | 15 | |||||
| Others Assetsⓘ | 20 | 24 | 41 | 54 | 134 | |||||
| Total Assets ⓘ | 228 | 254 | 370 | 556 | 719 | |||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 19 | 31 | 42 | 58 | 39 |
| PBT ⓘ | 24 | 38 | 46 | 89 | 78 |
| Adjustment ⓘ | 16 | 14 | 10 | 12 | 23 |
| Changes in Working Capital ⓘ | -17 | -12 | -1 | -22 | -43 |
| Tax Paid ⓘ | -4 | -9 | -13 | -21 | -19 |
| Cash Flow From Investing Activity ⓘ | -9 | -6 | -20 | -188 | -88 |
| Capex | -9 | -4 | -18 | -80 | -78 |
| Net Investments | -1 | 0 | 0 | 5 | -10 |
| Others ⓘ | 0 | -2 | -1 | -113 | 0 |
| Cash Flow From Financing Activityⓘ | -10 | -23 | -19 | 125 | 51 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -7 | -17 | -9 | 69 | 14 |
| Interest Paid ⓘ | -5 | -5 | -3 | -6 | -11 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 2 | -2 | -7 | 61 | 47 |
| Net Cash Flow ⓘ | 0 | 1 | 3 | -5 | 3 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 23.38 | 28.99 | 27.04 | 37.22 | 24.02 | |||||
| ROCE (%) | 19.19 | 26.58 | 28.42 | 32.59 | 21.7 | |||||
| Asset Turnover Ratio | 1.57 | 1.55 | 1.32 | 1.7 | 1.35 | |||||
| PAT to CFO Conversion(x) | 1 | 1.11 | 1.2 | 0.88 | 0.67 | Working Capital Days | ||||
| Receivable Days | 97 | 89 | 100 | 73 | 86 | |||||
| Inventory Days | 34 | 48 | 70 | 46 | 43 | |||||
| Payable Days | 76 | 107 | 123 | 89 | 100 | |||||
Innova Captab was incorporated in Mumbai, Maharashtra, as ‘Harun Health Care Private Limited’, a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 3, 2005, issued by the RoC. Thereafter, pursuant to a resolution passed by its Shareholders in the extraordinary general meeting held on December 26, 2009, the name of the Company was changed from ‘Harun Health Care Private Limited’ to ‘Innova Captab Private Limited’, in order to reflect innovations in the pharmaceutical sector. Consequently, a fresh certificate of incorporation dated February 2, 2010, was issued by the RoC to the company. Subsequently, the Company was converted from a private limited company to a public limited company, pursuant to a resolution passed by its Shareholders in the extraordinary general meeting held on July 12, 2018, and consequently, the name of the Company was changed to its present name ‘Innova Captab Limited’, and a fresh certificate of incorporation dated July 26, 2018, was issued by the RoC to the Company.
The company is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Its business includes (i) a contract development and manufacturing organization (CDMO) business providing manufacturing services to Indian pharmaceutical companies, (ii) a domestic branded generics business and (iii) an international branded generics business.
The company’s CDMO services and products include commercial large-scale manufacturing of generic products. It also enters into loan license agreements with its customers. Its comprehensive CDMO formulation capabilities allow it to offer its customers multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, as well as more complex delivery forms such as modified and sustained release forms and tablets in capsules. It also has added products using new technologies like nano technology. Its CDMO product portfolio spans across both acute and chronic therapeutic areas. It manufacture products across some of the key therapeutic areas identified by, including cephalosporins, proton pump inhibitors, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluroquinolone and macrolide, nootropics and neurotronic/neurotrophic, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorders, antifungal, anthelmintic and antiviral anticholinergic and anti-asthmatic and bronchodilator and erectile dysfunction.
The company’s branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its branded generic products are generic medicines for which the patents have expired, that are sold directly to its distributors, stockists and retailers. It has developed a diversified branded generics product portfolio including tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals. It sells its domestic branded generic products through its pan-Indian network of distributors, stockists and pharmacies.
Business area of the company
The company is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Its business includes (i) a CDMO business providing manufacturing services to Indian pharmaceutical companies, (ii) a domestic branded generics business and (iii) an international branded generics business.
Products of the company
Awards, accreditations or recognitions
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
